Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 25 | $24,241,429 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
13 May 2024 15:57 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 10 May 2024 | Sale | 20,000 | 81.14 | 1,622,800 | D |
13 May 2024 15:57 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 09 May 2024 | Sale | 20,000 | 81.62 | 1,632,400 | D |
06 May 2024 16:45 | BMRN | BIOMARIN PHARMACEUTICAL INC | DAVIS GEORGE ERIC | EVP, Chief Legal Officer | 02 May 2024 | Sale | 1,850 | 85.01 | 157,268 | D |
06 May 2024 16:40 | BMRN | BIOMARIN PHARMACEUTICAL INC | AJER JEFFREY ROBERT | EVP, Chief Commercial Officer | 02 May 2024 | Sale | 5,000 | 82.91 | 414,550 | D |
15 Apr 2024 16:21 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 12 Apr 2024 | Sale | 20,000 | 91.26 | 1,825,200 | D |
15 Apr 2024 16:21 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 11 Apr 2024 | Sale | 20,000 | 90.99 | 1,819,800 | D |
12 Apr 2024 15:07 | BMRN | BIOMARIN PHARMACEUTICAL INC | BURKHART ERIN | GVP, Chief Accounting Officer | 10 Apr 2024 | Sale | 2,286 | 90 | 205,740 | D |
01 Apr 2024 16:54 | BMRN | BIOMARIN PHARMACEUTICAL INC | DAVIS GEORGE ERIC | EVP, Chief Legal Officer | 28 Mar 2024 | Sale | 24,602 | 88.34 | 2,173,341 | D |
07 Mar 2024 18:54 | BMRN | BIOMARIN PHARMACEUTICAL INC | FUCHS HENRY J | President, Worldwide R&D | 05 Mar 2024 | Sale | 35,341 | 85.1814 | 3,010,396 | D |
07 Mar 2024 17:35 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 06 Mar 2024 | Sale | 1,000 | 86.713 | 86,713 | D |
07 Mar 2024 17:35 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 05 Mar 2024 | Sale | 1,000 | 85.51 | 85,510 | D |
07 Mar 2024 17:32 | BMRN | BIOMARIN PHARMACEUTICAL INC | AJER JEFFREY ROBERT | EVP, Chief Commercial Officer | 05 Mar 2024 | Sale | 4,000 | 87.07 | 348,280 | D |
29 Feb 2024 17:05 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 27 Feb 2024 | Sale | 1,000 | 90.35 | 90,350 | D |
12 Feb 2024 17:20 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 08 Feb 2024 | Sale | 15,000 | 89.77 | 1,346,550 | D |
12 Feb 2024 17:20 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 09 Feb 2024 | Sale | 15,000 | 88.28 | 1,324,200 | D |
11 Jan 2024 14:40 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 10 Jan 2024 | Sale | 10,000 | 96.38 | 963,800 | D |
11 Jan 2024 14:40 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 09 Jan 2024 | Sale | 10,000 | 98.19 | 981,900 | D |
22 Dec 2023 17:14 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Director | 21 Dec 2023 | Sale | 10,000 | 93.99 | 939,900 | D |
14 Dec 2023 18:18 | BMRN | BIOMARIN PHARMACEUTICAL INC | DAVIS GEORGE ERIC | EVP, Chief Legal Officer | 13 Dec 2023 | Sale | 13,764 | 95.3 | 1,311,709 | D |
17 Aug 2023 15:57 | BMRN | BIOMARIN PHARMACEUTICAL INC | AJER JEFFREY ROBERT | EVP, Chief Commercial Officer | 16 Aug 2023 | Sale | 5,000 | 90 | 450,000 | D |
11 Aug 2023 13:59 | BMRN | BIOMARIN PHARMACEUTICAL INC | FUCHS HENRY J | President, Worldwide R&D | 10 Aug 2023 | Sale | 12,000 | 90.4259 | 1,085,111 | D |
10 Aug 2023 16:47 | BMRN | BIOMARIN PHARMACEUTICAL INC | GUYER CHARLES GREG | EVP, Chief Technical Officer | 09 Aug 2023 | Sale | 5,360 | 93.304 | 500,109 | D |
09 Aug 2023 19:08 | BMRN | BIOMARIN PHARMACEUTICAL INC | DAVIS GEORGE ERIC | EVP, Chief Legal Officer | 08 Aug 2023 | Sale | 11,000 | 89.4238 | 983,662 | D |
09 Aug 2023 19:05 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Chief Executive Officer | 08 Aug 2023 | Sale | 6,000 | 88.29 | 529,740 | D |
09 Aug 2023 19:05 | BMRN | BIOMARIN PHARMACEUTICAL INC | BIENAIME JEAN JACQUES | Chief Executive Officer | 07 Aug 2023 | Sale | 4,000 | 88.1 | 352,400 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)